Categories Earnings, Health Care

Aethlon Medical earnings preview: Cash crunch at its peak ahead of Q4 results

Aethlon Medical (NASDAQ: AEMD) is trading near an all-time low as it heads towards its fourth-quarter financial results, slated for Monday, July 1, after the closing bell. On the back of consecutive disappointing results, Wall Street expects Q4 loss to widen by a cent to $0.07 per share.

In the trailing two quarters, the company had missed earnings expectations.

aethlon medical
The Aethlon Hemopurifier (Image courtesy: Aethlon Medical)

The medical device company is projected to report meager revenues of $50,000, representing a 33% dip compared to last year. The company’s Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. Hemopurifier has a “Breakthrough Device” designation from The United States Food and Drug Administration (FDA).

The biggest risk facing the company at the moment is shortage of funds. Its primary source of revenue is its contract with the National Institute of Health. Another such contract with the Defense Advanced Research Projects Agency ended recently and a lot would depend on the company’s success in finding another funder.

Increasing costs related to research and development, as well as clinical trials, are creating a financial burden, and the company estimates that it can go on for another year with the revenue sources it currently has.

READ: What is NASH and which biotech companies are vying for its first-mover status

Those who had stayed invested in the stock had a rough last year. The stock has declined 72% in the trailing 12 months, and 77% in the year-to-date period. And with little revenues and almost no profits, it’s hard to remain committed to the stock.

The stock also faces the risk of getting delisted if it continues to lose investor interest.

Meanwhile, the market still has a ray of hope for the stock. For the current fiscal year, analysts’ expect the company to narrow its losses to 33 cents per share, compared to 44 cents per share last year. The year after that, it is projected to slash its losses by another 10 cents per share.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

HD Stock: What’s in store for Home Depot after record second quarter

Home improvement is one of the top activities that kept Americans busy during the pandemic, a trend that enabled The Home Depot, Inc. (NYSE: HD) to beat the crisis and

Target (TGT) stock drops after Q2 earnings miss estimates; revenue up 4%

Department store chain Target Corporation (NYSE: TGT) reported a sharp decline in adjusted earnings for the second quarter of 2022, despite an increase in net sales. The bottom line also fell

Amazon (AMZN) stock remains a good bet despite poor results. Here’s why

Amazon.com, Inc. (NASDAQ: AMZN) became an inspiration for other players in the eCommerce sector as the online retailer successfully channelized its resources to tap into the spike in demand for

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top